"Low dose apixaban as secondary prophylaxis of venous thromboembolism in cancer patients-30 months follow-up": Comment from Serrao et al

J Thromb Haemost. 2022 Aug;20(8):1935-1937. doi: 10.1111/jth.15775.
No abstract available

Publication types

  • Letter
  • Comment

MeSH terms

  • Anticoagulants / adverse effects
  • Follow-Up Studies
  • Humans
  • Neoplasms* / complications
  • Neoplasms* / drug therapy
  • Pyrazoles
  • Pyridones / adverse effects
  • Venous Thromboembolism* / drug therapy

Substances

  • Anticoagulants
  • Pyrazoles
  • Pyridones
  • apixaban